DAUNORUBICIN WITH CYTARABINE

Brand name:

• Vyxeos®

Form and strength:

Please search for and view the medicine's Public Summary Document (PSD) for more information

Submission sponsor:

JAZZ PHARMACEUTICALS ANZ PTY LTD

Condition/indication:
(therapeutic use)

• Acute myeloid leukaemia

Listing requested:

Please see PSD for more information

Funding program:

Please see PSD for more information

Request authority level:

Please see PSD for more information

PBAC Submission type:

New PBS listing (Matters arising/Matters outstanding)

Comment:

This item was recommended out-of-session between the March 2024 PBAC Meeting and the July 2024 PBAC Meeting. No further action, please see DAUNORUBICIN WITH CYTARABINE link in Related medicines below.

Other PBAC consideration:

• DAUNORUBICIN WITH CYTARABINE
• DAUNORUBICIN WITH CYTARABINE

Submission received for:

July 2024 PBAC meeting

Opportunity for consumer comment:

Not applicable

PBAC meeting:

Not applicable

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

Not Applicable

Lodgement of required documentation:

Not applicable

Agreement to listing arrangements:

Not applicable

Government processes:

Not applicable

Medicine listed on the PBS:

Not applicable